These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27440271)

  • 1. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.
    Duran R; Mirpour S; Pekurovsky V; Ganapathy-Kanniappan S; Brayton CF; Cornish TC; Gorodetski B; Reyes J; Chapiro J; Schernthaner RE; Frangakis C; Lin M; Sun JD; Hart CP; Geschwind JF
    Clin Cancer Res; 2017 Jan; 23(2):536-548. PubMed ID: 27440271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer.
    Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA
    Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
    Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
    Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.
    van Breugel JMM; Geschwind JF; Mirpour S; Savic LJ; Zhang X; Duran R; Lin M; Miszczuk M; Liapi E; Chapiro J
    Theranostics; 2019; 9(13):3674-3686. PubMed ID: 31281506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
    Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
    Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
    BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
    Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
    Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
    Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
    Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
    Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).
    Tran NH; Foster NR; Mahipal A; Byrne T; Hubbard J; Silva A; Mody K; Alberts S; Borad MJ
    Invest New Drugs; 2021 Aug; 39(4):1072-1080. PubMed ID: 33646489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment.
    Savic LJ; Schobert IT; Peters D; Walsh JJ; Laage-Gaupp FM; Hamm CA; Tritz N; Doemel LA; Lin M; Sinusas A; Schlachter T; Duncan JS; Hyder F; Coman D; Chapiro J
    Clin Cancer Res; 2020 Jan; 26(2):428-438. PubMed ID: 31582517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model.
    Doemel LA; Santana JG; Savic LJ; Gaupp FML; Borde T; Petukhova-Greenstein A; Kucukkaya AS; Schobert IT; Hamm CA; Gebauer B; Walsh JJ; Rexha I; Hyder F; Lin M; Madoff DC; Schlachter T; Chapiro J; Coman D
    Eur Radiol; 2022 Apr; 32(4):2437-2447. PubMed ID: 34718844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.
    Brenner A; Zuniga R; Sun JD; Floyd J; Hart CP; Kroll S; Fichtel L; Cavazos D; Caflisch L; Gruslova A; Huang S; Liu Y; Lodi A; Tiziani S
    Neuro Oncol; 2018 Aug; 20(9):1231-1239. PubMed ID: 29415215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
    Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.
    Harms JK; Lee TW; Wang T; Lai A; Kee D; Chaplin JM; McIvor NP; Hunter FW; Macann AMJ; Wilson WR; Jamieson SMF
    Cells; 2019 Jul; 8(7):. PubMed ID: 31337055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transhepatic arterial embolization with superparamagnetic iron oxide and lipiodol for the treatment of VX2 tumor in rabbits].
    Liang Q; Deng L; Feng Z; Liu X; Ding J; Hu P; Wang W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Nov; 42(11):1248-1256. PubMed ID: 29187650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
    Hegde A; Jayaprakash P; Couillault CA; Piha-Paul S; Karp D; Rodon J; Pant S; Fu S; Dumbrava EE; Yap TA; Subbiah V; Bhosale P; Coarfa C; Higgins JP; Williams ET; Wilson TF; Lim J; Meric-Bernstam F; Sumner E; Zain H; Nguyen D; Nguyen LM; Rajapakshe K; Curran MA; Hong DS
    Clin Cancer Res; 2021 Jun; 27(11):3050-3060. PubMed ID: 33771853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of curcumin liposome after transcatheter arterial embolization in VX2 rabbits.
    Zhang X; Dai F; Chen J; Xie X; Xu H; Bai C; Qiao W; Shen W
    Cancer Biol Ther; 2019; 20(5):642-652. PubMed ID: 30621501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.